Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Arq. bras. endocrinol. metab ; 51(9): 1522-1527, dez. 2007. tab
Article in Portuguese | LILACS | ID: lil-471774

ABSTRACT

A hiperprolactinemia tumoral e conseqüente hipogonadismo têm sido associados à osteoporose. Avaliamos a densidade mineral óssea (DMO) por absortometria com dupla fonte de RX em 24 mulheres entre 18 e 49 anos, com prolactinoma (15 macro e 9 micro). Utilizamos teste t de Student não pareado ou Mann-Whitney para comparar subgrupos, e teste de Spearman para correlações. O maior acometimento foi de coluna lombar, onde 20,83 por cento das pacientes tinham Z-escore < -2 DP. Não detectamos diferenças densitométricas entre macro e microprolactinomas, nem entre pacientes com prolactina normal versus as hiperprolactinêmicas. A DMO e o Z-escore na coluna foram maiores nas pacientes com > 8 ciclos menstruais no ano anterior à densitometria versus as oligoamenorréicas (p = 0,030). O número de ciclos/ano correlacionou-se com a DMO na coluna (r = 0,515, p = 0,017), e o índice de massa corporal, com a DMO em colo femural (r = 0,563, p = 0,006) e fêmur total (r = 0,529, p = 0,011). Conclusões: Em nossa amostra de mulheres jovens com prolactinoma, 20,83 por cento têm densidade óssea abaixo do esperado para a idade. O maior acometimento de regiões ricas em osso trabecular, como as vértebras, sugere a participação do hipogonadismo na gênese da doença óssea. Independentemente dos valores séricos de prolactina, o retorno dos ciclos menstruais parece ser o melhor índice de bom controle dessas pacientes.


Tumoral hyperprolactinemia and consequent hypogonadism have been associated with osteoporosis. Bone mineral density (BMD) was measured by dual-energy RX absorptiometry in 24 patients with prolactinoma (15 macro and 9 micro adenomas; age range = 18 to 49 years). Student unpaired t or Mann-Whitney tests were used to compare groups, and Spearman test studied correlations. Lumbar spine (LS) was the most affected, as LS Z-score was < -2 SD in 20.83 percent of the patients. No difference was found in densitometric parameters for the comparison between macro and microprolactinoma, or those with normal prolactin versus hyperprolactinemia. LS BMD and LS Z-score were higher in the patients with > 8 menstrual cycles in the preceding year then in those with oligoamenorrhea (p = 0.030). The number of cycles was correlated to LS BMD (r = 0.515, p = 0.017) and body mass index to femoral neck BMD (r = 0.563, p = 0.006) and total femur BMD (r = 0.529, p = 0.011). CONCLUSIONS: Decreased bone mineral density was detected in 20.83 percent of our young patients with prolactinoma. The great involvement of trabecular bone skeletal regions, such as vertebrae, suggests the participation of hypogonadism in the pathogenesis of bone disease. Irrespective of prolactin levels, return to normal menses seems the best index of good control.


Subject(s)
Adolescent , Adult , Female , Humans , Middle Aged , Bone Density/physiology , Hyperprolactinemia/physiopathology , Osteoporosis/physiopathology , Pituitary Neoplasms/physiopathology , Premenopause/physiology , Prolactinoma/physiopathology , Confidence Intervals , Cross-Sectional Studies , Densitometry , Hyperprolactinemia/complications , Menstrual Cycle , Menstruation , Osteoporosis/complications , Pituitary Neoplasms/complications , Prolactinoma/complications , Statistics, Nonparametric
2.
Rev. sanid. mil ; 51(4): 192-6, jul.-ago. 1997.
Article in Spanish | LILACS | ID: lil-227361

ABSTRACT

Los prolactinomas son adenomas hipofisiarios frecuentes y son causa importante de infertilidad. Son más frecuentes en mujeres entre la segunda y quinta décadas de la vida. Morfólogicamente se clasifican como microprolactinomas (<10 mm) y macroprolactinomas (>10 mm). Sus manifestaciones pueden ser endocrinas (que son las más frecuentes) o por efecto de masa y neurológicas


Subject(s)
Humans , Male , Female , Prolactin , Prolactinoma/diagnosis , Prolactinoma/physiopathology , Prolactinoma/drug therapy , Bromocriptine/pharmacology , Dopamine Agonists , Endocrine System Diseases , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL